Evidence map›Paper›PMID 30057227›Full record

ArticleThe American journal of cardiology2018

Willingness to be Reinitiated on a Statin (from the REasons for Geographic and Racial Differences in Stroke Study).

Matthew T Mefford, Gabriel S Tajeu, Rikki M Tanner, Lisandro D Colantonio, Keri L Monda, Ricardo Dent, Michael E Farkouh, Robert S Rosenson, Monika M Safford, Paul Muntner

Open access · greenAbstract read
In one paragraph

Article in The American journal of cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Prevalence of statin intolerance: a meta-analysis.European heart journal · 2022 · on this map
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. A Mechanism for Statin-Induced Susceptibility to Myopathy.JACC. Basic to translational science · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Matthew T MeffordUniversity of Alabama at Birmingham, Birmingham, Alabama.
Gabriel S TajeuTemple University, Philadelphia, Pennsylvania.
Rikki M TannerUniversity of Alabama at Birmingham, Birmingham, Alabama.
Lisandro D ColantonioUniversity of Alabama at Birmingham, Birmingham, Alabama.
Keri L MondaAmgen, Inc., Thousand Oaks, California.
Ricardo DentAmgen, Inc., Thousand Oaks, California.
Michael E FarkouhPeter Munk Cardiac Centre and the Heart and Stroke Richard Lewar Centre, University of Toronto, Toronto, Ontario, Canada.
Robert S RosensonIcahn School of Medicine at Mount Sinai, New York, New York.
Monika M SaffordWeill Cornell Medicine, New York, New York.
Paul MuntnerUniversity of Alabama at Birmingham, Birmingham, Alabama. Electronic address: pmuntner@uab.edu.
University of Alabama at Birmingham · USAmgen (United States) · USCornell University · USIcahn School of Medicine at Mount Sinai · USTemple University · USUniversity of Toronto · CA

Funding

VCID and Stroke in a Bi-racial National CohortU01NS041588 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CUSHMAN, MARY, HOWARD, GEORGE · 2002 to 2022
$96.0M
AHRQ HHS T32 HS013852NINDS NIH HHS U01 NS041588
6 · The paper itself

Abstract

Guidelines recommend attempting to reinitiate statins in patients who discontinue treatment. Previous experiences while taking a statin, including side effects, may reduce a patient's willingness to reinitiate treatment. We determined the percentage of adults who are willing to reinitiate statin therapy after treatment discontinuation. Factors associated with willingness to reinitiate a statin were also examined. A statin questionnaire was administered and study examination conducted in black and white US adults enrolled in the nationwide REasons for Geographic And Racial Differences in Stroke study from 2013 to 2017. In participants who self-reported ever having taken a statin (n = 7,216, mean age 72 years, 53% women, 34% black), 1,081 (15%) reported having discontinued treatment. Among those who discontinued treatment, statin side effects, perceived lack of need for a statin, and cost were reported by 66%, 31%, and 3% of participants, respectively. Overall, 37% of participants who had discontinued treatment were willing to reinitiate statin therapy. Participants who discontinued treatment due to cost (prevalence ratio [PR] 1.61; 95% confidence interval (CI) 1.01, 2.57) were more likely to report a willingness to reinitiate therapy. Participants with a low-density lipoprotein-cholesterol ≥130 mg/dl versus <100 mg/dl (PR 0.69; 95% CI 0.53, 0. 88) and who discontinued treatment due to side effects (PR 0.51; 95% CI 0.41, 0.64) were less likely to report willingness to reinitiate statin therapy. In conclusion, a substantial proportion of participants who discontinued statin therapy were willing to reinitiate treatment. Healthcare providers should discuss reinitiation of statin therapy with their patients who have discontinued treatment.

Indexed as

Medication AdherenceAgedFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedStrokeUnited StatesHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID30057227
PMCPMC9581445
OpenAlexW2807539078

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.